The Pharmacology Center

Filter Your Results





With Moderator Andrey Espinoza, MD, FACC, FSCAI; and Panelists Peter B. Berger, MD; Paul A. Gurbel, MD; Charles Pollack, MA, MD, FACEP, FAAEM; and Marc Cohen, MD, FACC

January/February 2016—A panel of experts weighs in on STEMI pharmacology, transmission of prehospital ECGs by emergency medical services, and STEMI best practices for 2016.

Optimal Duration of DAPT

Sammy Elmariah, MD, MPH, FACC, FAHA

January/February 2016—Data and implications of recent trials.

Benefits and Risks of Extended DAPT After EES Studied

January 25, 2016 -- Findings from a study of dual-antiplatelet therapy that aimed to characterize outcomes for everolimus-eluting stent (EES) -- treated patients according to …

Antiplatelet Monotherapies Compared After 12-Month DAPT Post-DES Implantation

January 21, 2016 -- Findings from an institutional registry investigation of the efficacy and safety of clopidogrel versus aspirin monotherapy after 12-month dual-antiplatelet…

Analysis of CHAMPION PHOENIX Trial Evaluates Cangrelor in Women During PCI

January 22, 2016 -- Michelle L. O’Donoghue, MD, et al published findings on the efficacy and safety of cangrelor in women versus men during percutaneous coronary interve…

Study Evaluates Factors Affecting Bleeding and Stent Thrombosis in Clinical Trials Comparing Bivalirudin With Heparin During PCI

December 23, 2015 -- John A. Bittl, MD, et al investigated factors affecting bleeding and stent thrombosis in clinical trials comparing bivalirudin with heparin during percuta…

Study Shows Premature Clopidogrel Discontinuation After DES in a Poor, Urban Patient Population

December 7, 2015 -- Noting that premature clopidogrel discontinuation is an important cause of stent thrombosis, myocardial infarction, and death after drug-eluting stent (DES…

Boehringer Ingelheim’s Praxbind Approved in Europe for Reversal of Pradaxa

November 26, 2015 -- Boehringer Ingelheim Pharmaceuticals announced that the European Commission has approved Praxbind (idarucizumab), a treatment to rapidly and specifically …



2018 Buyer’s Guide

This Buyer’s Guide offers a searchable, comprehensive listing of the FDA-approved interventional devices available in the United States.


Contact Info

For advertising rates and opportunities, contact:
Craig McChesney

Stephen Hoerst

Charles Philip

About Cardiac Interventions Today

Cardiac Interventions Today (ISSN 2572-5955 print and ISSN 2572-5963 online) is a publication dedicated to providing comprehensive coverage of the latest developments in technology, techniques, clinical studies, and regulatory and reimbursement issues in the field of coronary and cardiac interventions. Cardiac Interventions Today premiered in March 2007 and each edition contains a variety of topics in a flexible format, including articles covering various perspectives on current clinical topics, in-depth interviews with expert physicians, overviews of available technologies, industry news, and insights into the issues affecting today's interventional cardiology practices.